Peer Reviewed

1

Document Type

Article

Publication Date

24-8-2017

Keywords

Aged, Cardiovascular diseases, Cognition disorders, Dyslipidemia, Hypertension, Medication adherence.

Funder/Sponsor

Health Research Board (grants no. SPHeRE/2013/1 and RLA/2015/1579). Irish Department for Health and Children.

Comments

This is the peer reviewed version of the following article: Rohde D, Hickey A, Williams D, Bennett K. Cognitive impairment and cardiovascular medication use: Results from wave 1 of The Irish Longitudinal Study on Ageing. Cardiovascular Therapeutics. 2017;35(6):, which has been published in final form at https://onlinelibrary.wiley.com/doi/epdf/10.1111/1755-5922.12300 . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Abstract

AIM: To explore the association between cardiovascular medication use and cognitive impairment in adults aged 50 years and over.

METHOD: This cross-sectional linked database study involved secondary quantitative analysis of 1903 participants from wave 1 of the Irish Longitudinal Study on Ageing with available pharmacy claims data. Cognitive impairment was assessed using a cut-off of ≤23 on the Montreal Cognitive Assessment. Cardiovascular medication use was calculated using the proportion of days covered for antihypertensive, antithrombotic, and lipid-modifying medications. For each class of cardiovascular medication, participants were categorized as belonging to one of three medication use groups: (1) not dispensed any medications (reference); (2) poor adherence (proportion of days covered

RESULTS: Controlling for demographic and health variables, there was no evidence of an independent association between impaired cognitive function and use of antihypertensives [good adherence OR (95% CI): 1.16 (0.88, 1.52), poor adherence OR (95% CI): 1.39 (0.95, 2.04)]; antithrombotics [good adherence OR (95% CI): 1.26 (0.93, 1.70), poor adherence OR 95% CI): 1.13 (0.80, 1.59)]; or lipid-modifying agents [good adherence OR (95% CI): 0.95 (0.71, 1.25), poor adherence OR (95% CI): 0.88 (0.64, 1.22)].

CONCLUSION: We found no evidence of an association between cardiovascular medication use and cognitive function. Future studies should investigate the prospective associations between cognition and use of cardiovascular medications using longitudinal data.

Disciplines

Cardiovascular Diseases | Epidemiology | Psychology

Citation

Rohde D, Hickey A, Williams D, Bennett K. Cognitive impairment and cardiovascular medication use: Results from wave 1 of The Irish Longitudinal Study on Ageing. Cardiovascular Therapeutics. 2017;35(6):

PubMed ID

28836733

DOI Link

10.1111/1755-5922.12300

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.

Share

COinS